Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma

International Journal of Biological Markers

Volumn 27, Issue 1, 2012, Pages 27-33

  Bagadi, Sarita B ^a   Sanghvi, Meera ^a   Nair, Sudish B ^a   Das, Bibhu R ^a  

^a Research and Development Division   (India)

Author keywords

BRAF; Colorectal carcinoma; EGFR; KRAS; NRAS

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CODON; COLON; COLORECTAL CARCINOMA; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EXON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIA; INDIAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RECTUM; TISSUE SECTION; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84863940087     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9108     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
3. Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008; 8: 413-418.
4. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324.
5. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
6. Sartore-Bianchi F, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-target-ed monoclonal antibodies. Cancer Res 2009; 69: 1851-1857.
7. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
8. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4: e7287.
9. Barault L, Veyrie N, Jooste V, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122: 2255-2259.
10. Prenen H, De Schutter J, Jacobs B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal Clin Cancer Res 2009; 15: 3184-3188.
11. Lambrechts D, Roock WD, Prenen H, et al. The role of KRAS, BRAF, NRAS and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol 2009; 27:15s (abstr 4020).
12. De Roock W, Lambrechts D, Tejpar S. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 2009; 360: 834-836.
13. Velho S, Moutinho C, Cirnes L, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis. BMC Cancer 2008; 8: 255.
14. Calistri D, Rengucci C, Seymour I, et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol 2005; 204: 484-488.
15. Wu CM, Tang R, Wang JY, et al. Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet 2005; 158: 55-60.
16. Irahara N, Baba Y, Nosho K, Shima K. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010; 19: 157-163.
17. Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of KRAS gene in colorectal cancer patients of Kashmir: A report. Indian J Cancer 2009; 46: 219-225.
18. Wójcik P, Kulig J, Okoń K, et al. KRAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in KRAS. Pol J Pathol 2008; 59: 93-96.
19. Shih LY, Huang CF, Wang PN, et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelo-dysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 466-475.
20. Sapio MR, Posca D, Troncone G, et al. Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006; 154: 341-348.
21. Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T. p53 and KRAS gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol 2000; 53: 24-30.
22. Fransén K, Klintenäs M, Osterström A, Dimberg J, Monstein HJ, Söderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004; 25: 527-533.
23. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K- ras, p53 and APC mutations in colorectal carcinoma. Gut 2005; 54: 1283-1286.
24. Lurkin I, Stoehr R, Hurst CD, et al. Two multiplex assays that simultaneously identify 22 possible mutation sites in the RAS, BRAF, NRAS and PIK3CA genes. PLoS One 2010; 5: e8802.
25. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the transla-tional study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474.
26. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21: 2396-2402.
27. Liang W, Julie MC, Jennifer LW et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003; 63; 5209-5212.
28. Gimbel MI, Nash G, Ndubuisi M, Wong D, Barany F, Paty P. Braf mutations are associated with increased mortality in colorectal cancer. J Am Coll Surg 2004; 199: 92.
29. Busby K, Morris A. Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay. Clin Pathol 2005; 58: 372-375.
30. Siu T Y, Helen D, Tsun LC, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-6455.
31. Wadler S, Bajaj R, Neuberg D, Agarwal V, Haynes H, Benson AB. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the Eastern Cooperative Oncology Group (EST2292). Cancer J Sci Am 1997; 3: 284-288.
32. Suchy B, Zietz C, Rabes HM. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992; 52: 30-33.
33. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slat-tery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-1197.
34. Gaedcke J, Grade M, Jung K, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradio-therapy. Radiother Oncol 2010; 94: 76-81.
35. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gab-bert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-799.
36. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60: 116-129.